Tarsus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Tarsus Pharmaceuticals
TARS Stock  USD 50.22  2.01  3.85%   
Tarsus Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Tarsus Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Tarsus Pharmaceuticals financial statements helps investors assess Tarsus Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Tarsus Pharmaceuticals' valuation are summarized below:
Gross Profit
70.7 M
Profit Margin
(1.04)
Market Capitalization
1.9 B
Enterprise Value Revenue
12.9234
Revenue
129.6 M
There are over one hundred nineteen available fundamental trend indicators for Tarsus Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should double-check Tarsus Pharmaceuticals' current fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 793.8 M in 2025. Enterprise Value is likely to gain to about 635.7 M in 2025

Tarsus Pharmaceuticals Total Revenue

24.52 Million

Check Tarsus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tarsus Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 7.8 M or Depreciation And Amortization of 529.3 K, as well as many indicators such as Price To Sales Ratio of 32.23, Dividend Yield of 0.0 or PTB Ratio of 2.85. Tarsus financial statements analysis is a perfect complement when working with Tarsus Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Tarsus Pharmaceuticals Correlation against competitors.
For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.

Tarsus Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets165.9 M305.3 M87.2 M
Slightly volatile
Other Current Liabilities22.2 M21.1 M5.1 M
Slightly volatile
Total Current Liabilities44.6 M42.5 M9.9 M
Slightly volatile
Property Plant And Equipment Net4 M3.9 M1 M
Slightly volatile
Accounts Payable21.9 M20.9 M4.6 M
Slightly volatile
Cash271.6 M258.7 M77.8 M
Slightly volatile
Non Current Assets Total11.3 M10.8 M2.4 M
Slightly volatile
Cash And Short Term Investments154.9 M261.6 M80 M
Slightly volatile
Net Receivables21.4 M20.4 M4 M
Slightly volatile
Common Stock Total Equity3.5 K5.8 K2.4 K
Slightly volatile
Common Stock Shares Outstanding21.8 M33.8 M13 M
Slightly volatile
Liabilities And Stockholders Equity165.9 M305.3 M87.2 M
Slightly volatile
Non Current Liabilities Total21.9 M36.3 M12.9 M
Slightly volatile
Other Current Assets9.5 M9 M2.6 M
Slightly volatile
Other Stockholder Equity533.3 M507.9 M137.3 M
Slightly volatile
Total Liabilities82.7 M78.8 M23.8 M
Slightly volatile
Property Plant And Equipment Gross5.6 M5.3 M1.2 M
Slightly volatile
Total Current Assets162.9 M294.6 M85.3 M
Slightly volatile
Capital Stock3.9 K5.8 K2.4 K
Slightly volatile
Net Working Capital150 M252.1 M77.4 M
Slightly volatile
Common Stock3.9 K5.8 K2.4 K
Slightly volatile
Property Plant Equipment711.5 K1.1 M378.2 K
Slightly volatile
Short and Long Term Debt Total38.3 M36.5 M8.2 M
Slightly volatile
Non Currrent Assets Other1.8 M1.7 M392 K
Slightly volatile
Other Assets0.860.992.8 K
Slightly volatile
Inventory2.7 M2.8 M22.8 M
Pretty Stable
Short Term Debt609.6 K457.7 K275.9 K
Slightly volatile
Other Liabilities58.1 K43.2 K58 K
Very volatile
Capital Surpluse261.8 M347 M225.8 M
Slightly volatile
Non Current Liabilities Other2.1 M2 M832.7 K
Slightly volatile
Current Deferred Revenue557.6 K627.3 K683.9 K
Slightly volatile
Long Term Debt27.1 M34.3 M21.5 M
Slightly volatile
Intangible Assets3.1 M3.5 M3.8 M
Slightly volatile

Tarsus Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization529.3 K1 M277.1 K
Slightly volatile
Selling General Administrative97 M92.4 M22.1 M
Slightly volatile
Other Operating Expenses193.9 M184.7 M46.3 M
Slightly volatile
Research Development60.8 M57.9 M17.7 M
Slightly volatile
Total Operating Expenses192 M182.9 M45.8 M
Slightly volatile
Reconciled Depreciation758.3 K722.2 K192.2 K
Slightly volatile
Cost Of Revenue1.1 M1.8 M533 K
Slightly volatile
Interest Income11.5 M10.9 M2.3 M
Slightly volatile

Tarsus Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation23.9 M22.8 M5.6 M
Slightly volatile
Begin Period Cash Flow86.4 M82.4 M40 M
Slightly volatile
Depreciation1.1 M1 M232.7 K
Slightly volatile
Capital Expenditures1.8 M1.7 M426.8 K
Slightly volatile
Issuance Of Capital Stock83.9 M114.3 M42.8 M
Slightly volatile
Total Cash From Financing Activities76.8 M149.7 M42.1 M
Slightly volatile
End Period Cash Flow271.6 M258.7 M77.9 M
Slightly volatile
Change To Netincome16.9 M16.1 M5 M
Slightly volatile
Change To Liabilities2.8 M4 M1.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio32.2330.6913.02
Slightly volatile
Days Sales Outstanding35033469.5016
Slightly volatile
Stock Based Compensation To Revenue1.071.020.3454
Slightly volatile
Capex To Depreciation3.221.973.8991
Slightly volatile
EV To Sales10.720.738.0066
Slightly volatile
Inventory Turnover0.560.592.454
Slightly volatile
Days Of Inventory On Hand702641531
Slightly volatile
Payables Turnover0.0750.0790.0916
Slightly volatile
Sales General And Administrative To Revenue0.871.570.7042
Slightly volatile
Average Inventory2.5 M3.5 M2.6 M
Slightly volatile
Research And Ddevelopement To Revenue1.412.61.0826
Slightly volatile
Capex To Revenue0.08140.07750.0242
Slightly volatile
Cash Per Share4.96.973.3109
Slightly volatile
Days Payables Outstanding2 K3.7 K2.4 K
Pretty Stable
Intangibles To Total Assets0.01170.01310.0143
Slightly volatile
Net Debt To EBITDA1.61.693.3247
Pretty Stable
Current Ratio7.587.9717.1732
Very volatile
Receivables Turnover1.081.13466
Slightly volatile
Graham Number24.9623.778.5925
Slightly volatile
Capex Per Share0.04830.0460.015
Slightly volatile
Revenue Per Share0.650.682.2666
Slightly volatile
Interest Debt Per Share1.131.070.2843
Slightly volatile
Debt To Assets0.110.11950.0295
Slightly volatile
Operating Cycle610974345
Slightly volatile
Days Of Payables Outstanding2 K3.7 K2.4 K
Pretty Stable
Ebt Per Ebit1.121.091.0093
Slightly volatile
Long Term Debt To Capitalization0.0880.120.0956
Slightly volatile
Quick Ratio7.487.8817.1352
Very volatile
Net Income Per E B T0.80.90.9819
Slightly volatile
Cash Ratio6.657.016.2306
Very volatile
Days Of Inventory Outstanding702641531
Slightly volatile
Days Of Sales Outstanding35033469.5016
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.21.0202
Slightly volatile
Fixed Asset Turnover5.695.9925.4934
Slightly volatile
Debt Ratio0.110.11950.0295
Slightly volatile
Price Sales Ratio32.2330.6913.02
Slightly volatile
Asset Turnover0.07180.07560.2595
Slightly volatile
Gross Profit Margin1.051.040.9703
Slightly volatile

Tarsus Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap793.8 M756 M381.5 M
Slightly volatile
Enterprise Value635.7 M605.4 M315.5 M
Slightly volatile

Tarsus Fundamental Market Drivers

Cash And Short Term Investments227.4 M

Tarsus Upcoming Events

11th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
11th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tarsus Pharmaceuticals Financial Statements

Tarsus Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Tarsus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Tarsus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tarsus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue627.3 K557.6 K
Total Revenue20.1 M24.5 M
Cost Of Revenue1.8 M1.1 M
Stock Based Compensation To Revenue 1.02  1.07 
Sales General And Administrative To Revenue 1.57  0.87 
Research And Ddevelopement To Revenue 2.60  1.41 
Capex To Revenue 0.08  0.08 
Revenue Per Share 0.68  0.65 
Ebit Per Revenue(9.44)(8.96)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY